Evidence map›Paper›PMID 38116135›Full record

ArticleFrontiers in cellular and infection microbiology2023

Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of

Hai Yang, Zhen Huang, Jiali Yue, Jianqi Chen, Mingming Yu, Chengming Qu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug-Resistance UropathogenicThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Enhancing the destruction ofFrontiers in cellular and infection microbiology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hai YangAffiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, China.
Zhen HuangAffiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, China.
Jiali YueSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Jianqi ChenSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Mingming YuSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Chengming QuAffiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, China.
Ocean University of China · CNQingdao University · CNAffiliated Hospital of Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of

Indexed as

AmikacinPseudomonas InfectionsAnti-Bacterial AgentsHumansMeropenemMicrobial Sensitivity TestsPseudomonas aeruginosaAmikacinAnti-Bacterial AgentsMeropenemamikacinLC-MS/MSmeropenemmetabolomicsPseudomonas aeruginosa

Identifiers

PMID38116135
PMCPMC10728327
OpenAlexW4389345400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.